吐温40 | 1052273-76-3

• 物质功能分类: 表面活性剂 - 非离子表面活性剂 - 多元醇酯型
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 吐温40
• 中文别名: 吐温-40；山梨醇酐聚乙二醇棕榈酸酯300；吐温4；聚山梨酯40；乳化剂T-40；聚氧乙烯山梨醇酐单棕榈酸酯；聚山梨醇酯40；吐温 40
• 英文名称: Tween 20
• 英文别名: 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl dodecanoate
• CAS: 1052273-76-3；9005-66-7；9005-64-5
• 化学式: C₂₆H₅₀O₁₀
• 分子量: 522.7
• InChiKey: HMFKFHLTUCJZJO-UHFFFAOYSA-N

物化性质

• 熔点：
  98.9 °C (decomp)
• 沸点：
  100 °C
• 密度：
  1.11 g/mL at 20 °C
• 闪点：
  >230 °F
• 溶解度：
  100g/l
• 物理描述：
  A lemon to amber-coloured oily liquid at 25 °C with a faint characteristic odour
• 颜色/状态：
  Lemon- to amber-colored liquid
• 气味：
  Characteristic odor
• 味道：
  Bitter
• 稳定性/保质期：
  在常温常压下保持稳定，请避免光照、明火及高温环境。
• 分解：
  When heated to decomposition it emits acrid smoke and irritating fumes.
• 折光率：
  Index of refraction = 1.468 at 20 °C
• 酸价：
  Not more than 2

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  36
• 可旋转键数：
  26
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  10

ADMET

代谢

大鼠对聚山梨酯的代谢已经通过14C标记示踪技术进行了详细研究。当口服给药时，聚山梨酯分子的酯键被胰腺脂肪酶水解，释放出的脂肪酸部分被吸收并像其他膳食脂肪酸一样被代谢。

The metabolism of Polysorbates in rats has been studied in detail with 14C-label tracer techniques. When administered orally, the ester link of the Polysorbate molecule is hydrolyzed by pancreatic lipase, and the fatty acid moiety is released to be absorbed and metabolized as any other dietary fatty acid.

来源:Hazardous Substances Data Bank (HSDB)

代谢

在大鼠静脉注射后，酯键被血液中的脂肪酶水解。当聚山梨酯20注射到大鼠体内时，标记的月桂酸部分被代谢，主要以呼出的CO2形式出现。由于在标记分子的这一部分时没有回收放射性物质作为CO2，因此可以认为聚氧乙烯部分没有被分解代谢。大部分标记的聚氧乙烯出现在尿液中，但也有一些存在于粪便中，表明有胆汁排泄。

After intravenous injection into rats, the ester bond is hydrolyzed by blood lipases. When Polysorbate 20 was injected into rats, the labeled lauric acid moiety was metabolized and appeared mostly as expired CO2. The polyoxyethylene moiety was not catabolized, since no radioactivity was recovered as CO2 when this portion of the molecule was labeled. Most of the labeled polyoxyethylene appeared in the urine, but some was present in the feces, indicating biliary excretion.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

非离子表面活性剂通常用作药物制剂中的辅料，但最近的研究表明，这些成分会影响活性药物的药代动力学。然而，其机制在很大程度上尚不清楚。在这里，我们使用咪达唑仑作为探针，体外和体内研究了四种常见非离子表面活性剂——聚山梨酯20、聚氧乙烯35蓖麻油、聚氧乙烯40硬脂酸酯和泊洛沙姆188对细胞色素P450 3A的影响。这些表面活性剂在大鼠肝脏和肠道微粒体中对咪达唑仑1'-羟基化的影响进行了研究。所有测试的表面活性剂都以浓度依赖性方式抑制咪达唑仑1'-羟基化，并在体外呈现混合竞争性抑制模型，表现为V(max)降低和K(m)值增加。在测试的非离子表面活性剂中，聚山梨酯20是对咪达唑仑1'-羟基化最有效的抑制剂，在大鼠肝脏和肠道微粒体中的IC(50)分别为2.06和0.39mg/mL。这些表面活性剂也在体内对大鼠咪达唑仑的药代动力学进行了测试。这四种表面活性剂在咪达唑仑和1'-羟基咪达唑仑的AUC方面表现出不同的抑制模式。聚山梨酯20显著增加了咪达唑仑的AUC(0-4小时)和AUC(0-无限大)，并使1'-羟基咪达唑仑的AUC(0-4小时)降低到约40%（p<0.05），在单次和多次处理的 rats中，1'-羟基咪达唑仑/咪达唑仑的代谢比显著降低到25%。聚氧乙烯35蓖麻油、聚氧乙烯40硬脂酸酯和泊洛沙姆188对咪达唑仑1'-羟基化显示出复杂的抑制作用，这取决于给药方案。这些结果证实了这些表面活性剂对细胞色素P450 3A具有潜在的抑制作用，并改变了咪达唑仑的生物利用度。因此，在选择药物制剂中的非离子表面活性剂时需要谨慎。

Nonionic surfactants are commonly used as excipients in pharmaceutical formulation, but recent studies demonstrate that the ingredients affect the pharmacokinetics of the active drugs. However, the mechanisms are largely unknown. Here, ... the effects of four common nonionic surfactants polysorbate 20, polyoxyl 35 castor oil, polyoxyl 40 stearate and poloxamer 188, on cytochrome P450 3A /were examined/ in vitro and in vivo using midazolam as a probe. ... The effects of these surfactants on the 1'-hydroxylation of midazolam /were examined/ in isolated rat liver and intestinal microsomes. All the surfactants tested inhibited midazolam 1'-hydroxylation in a concentration-dependent manner and presented a mixed competitive inhibitory model with decreased V(max) and increased K(m) values in vitro. Among the tested nonionic surfactants, polysorbate 20 was the most potent inhibitor of midazolam 1'-hydroxylation with an IC(50) of 2.06 and 0.39mg/mL in the liver and intestinal microsomes, respectively. These surfactants were also tested in vivo ... on the pharmacokinetics of midazolam in rats. These four surfactants displayed different inhibitory patterns in terms of the AUC of midazolam and 1'-hydroxymidazolam. Polysorbate 20 significantly increased both AUC(0-4 hr) and AUC(0-infinity) of midazolam and decreased the AUC(0-4 hr) of 1'-hydroxymidazolam to about 40% (p<0.05) in both single- and multiple-treated rats, along with a significant decrease of the metabolic ratio of 1'-hydroxymidazolam/midazolam to 25%. Polyoxyl 35 castor oil, polyoxyl 40 stearate and poloxamer 188 displayed complicated inhibition on the 1'-hydroxylation of midazolam dependent on the administration formula. These results confirmed that effects of these surfactants would have potential inhibitory effects on cytochrome P450 3A and altered midazolam bioavailability. Therefore, caution is needed when selecting nonionic surfactants in drug formulation.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、球囊阀面罩设备或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果患者呕吐，让患者向前倾或将其置于左侧（如果可能的话，头部向下）以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗救助。 /毒物A和B/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 基本治疗：建立专利气道（如有需要，使用口咽或鼻咽气道）。如有必要，进行吸痰。观察呼吸不足的迹象，如有需要，辅助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要，进行治疗……。监测休克，如有必要，进行治疗……。预防癫痫发作，如有必要，进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用0.9%的生理盐水（NS）持续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的干呕反射且不流口水，则用温水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干燥的无菌敷料覆盖皮肤烧伤……。/毒药A和B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最低流量/。如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

人体暴露研究/ 德雷兹-谢兰斯基测试包括在诱导贴片1、4、7和10之后以及挑战贴片之后的紫外线暴露。使用含有聚山梨酯20和60的产品时，很少有刺激的例子，并且没有表明光敏化的反应。

/HUMAN EXPOSURE STUDIES/ The Draize-Shelanski tests included UV exposure after induction patches 1, 4, 7, and 10 and after the challenge patch. With products containing Polysorbates 20 and 60, there were few instances of irritation and no reactions indicative of photosensitization.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

调查人员发现，聚山梨酯20中的标记月桂酸部分被大鼠迅速吸收并氧化。24小时后，大约75%的月桂酸被氧化并以二氧化碳形式排出，4%没有从消化道中被吸收。

/Investigators/ found that the labeled lauric acid moiety of Polysorbate 20 was rapidly absorbed and oxidized by rats. After 24 hours, some 75 percent of the lauric acid was oxidized and expired as CO2. 4 percent was not absorbed from the alimentary tract.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

聚氧乙烯山梨坦部分在酯水解后从大鼠的胃肠道吸收不良。在一项研究中，将放射性碳标记在聚山梨酯20的聚氧乙烯部分，90%从粪便中排出，8%从尿液中排出。在肝脏、尸体或呼出的二氧化碳中没有发现放射性。

The polyoxyethylene sorbitan moiety left after hydrolysis of the ester is poorly absorbed from the rat's gastrointestinal tract. In one study with a radioactive carbon label in the polyoxyethylene portion of Polysorbate 20, 90 percent was excreted in the feces and 8 percent in the urine. No radioactivity was found in the liver, carcass, or expired C02.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

静脉注射聚山梨酯20到大鼠体内后，标记的月桂酸部分的分布情况如下：呼出的二氧化碳中占68%，尸体中占22%，尿液中占5%，粪便和胃肠道内容物中占2.5%，肝脏中占0.7%。标记的聚氧乙烯部分的分布情况如下：尿液中占83%，粪便中占11%，尸体中占2%，肝脏中占0.15%，呼出的二氧化碳中没有发现。

After intravenous injection of Polysorbate 20 into rats, the distribution of the labeled lauric acid moiety was: expired CO2, 68 percent; carcass, 22 percent; urine, 5 percent; feces and gastrointestinal contents, 2.5 percent; and liver 0.7 percent. The distribution of the labeled polyoxyethylene moiety was: urine, 83 percent; feces, 11 percent; carcass, 2 percent; liver, 0.15 percent; and expired CO2 nil.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

调查人员给大鼠喂食聚山梨酯20，并追踪了标记的月桂酸在各种组织中的分布。口服给药后大约24小时，放射性的大致分布为：呼出的二氧化碳，80%；尸体，12%；未被胃肠道吸收，4%；尿液，2.5%；肝脏，1.2%。

/Investigators/ fed Polysorbate 20 to rats and followed the distribution of labeled lauric acid to various tissues. The approximate distribution of radioactivity 24 hours after oral administration was: expired C02, 80 percent; carcass, 12 percent; unabsorbed from the gastrointestinal tract, 4 percent; urine, 2.5 percent; and liver, 1.2 percent.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• TSCA：
  Yes

制备方法与用途

表面活性剂 - 吐温20

吐温20是一种表面活性剂，为黄色或琥珀色的油状液体，具有特殊的臭气和微弱苦味。通常作为稳定剂应用于生物制品的生产过程或最终制剂中。它是由山梨糖醇酐单月桂酸酯与氧化乙烯反应制得。

鉴别试验

• 溶解性：溶于水、乙醇、甲醇、乙酸乙酯和二嗯烷；不溶于矿物油和石油醚。
• 脂肪酸试验：取5%试样液5ml，加氢氧化钠试液（TS-224）5ml。煮沸数分钟，冷却后用稀盐酸试液（TS-117）酸化。由于释出脂肪酸，溶液呈强乳白色。
• 与“聚氧乙烯(8)硬脂酸酯(10021)”中的鉴别方法3相同。
• 皂化：100g吐温20试样经碱皂化后，约可产生16g脂肪酸类和8g多元醇类。测定方法见“聚氧乙烯(8)硬脂酸酯(10021)”。

含量分析

按OT-36方法测定环氧乙烷含量。

毒性

• ADI：0～25mg/kg（FAO/WHO，2001）。
• LD50：37g/kg（大鼠，经口）。

使用限量

• 适度为限（FDA§172.515，2000）。
  • FEMA(mg/kg)：饮料41；糖果75。
• 提高人体对液体石蜡和其他脂溶性物质的吸收能力。
• GB 2760-1996(g/kg)：月饼0.5；果汁饮料0.75；雪糕1.5；植物蛋白饮料2.0。

化学性质

• 外观呈琥珀色黏稠液体，有轻微特殊臭味和微苦。
• 相对密度为1.08～1.13，沸点321℃。
• 溶于水、乙醇、甲醇和乙酸乙酯；不溶于矿物油和石油醚。
• HLB值为16.7。
• 大白鼠经口LD50：37g/kg；ADI 0～25mg/kg（FAO/WHO，1994）。
• 吐温20是一种非离子表面活性剂。

用途

• 作O/W型食品乳化剂，单独使用或与司盘-60、司盘-65、司盘-80 混合使用。我国规定可用于雪糕（最大使用量1.5g/kg）、果汁饮料（最大用量0.75g/kg）和月饼（最大用量0.5g/kg）。
• 吐温20属水包油型乳化剂，可用作增溶剂、扩散剂、稳定剂、润滑剂和抗静电剂。
  • 在石油开采中作为油井生产的防蜡剂，可以清除油井的结蜡；作为降粘剂可以降低原油流动粘度提高油井产量，提高输送能力。
  • 在医药、日用化工中用作药品和化妆品的增溶剂、渗透剂和分散剂。
  • 因具有防锈性和润滑性而用于制备防锈润滑油和除锈去脂迹油。

生产方法

1. 将1 mol斯盘20投入反应釜中，在搅拌下加50%液碱作催化剂，逐渐升温，减压脱水。

2. 将水脱尽后用氮气置换釜中的空气，驱净空气后升温至120℃开始通入20 mol环氧乙烷，反应温度维持在150～170℃，压力0.2～0.3 MPa。通完环氧乙烷后，冷却至80～90℃，将料液打入中和釜用冰醋酸中和。

3. 再用双氧水脱色，最后冷却脱色，冷却放料，包装即为吐温20。

4. 在甲醇钠（或乙醇钠）的催化下，在130～170℃时，在span-20中通入一定量的环氧乙烷发生加成反应得吐温20。

文献信息

• [EN] 3-[(HYDRAZONO)METHYL]-N-(TETRAZOL-5-YL)-BENZAMIDE AND 3-[(HYDRAZONO)METHYL]-N-(1,3,4-OXADIAZOL-2-YL)-BENZAMIDE DERIVATIVES AS HERBICIDES<br/>[FR] DÉRIVÉS DE 3-[(HYDRAZONO))MÉTHYL]-N-(TÉTRAZOL-5-YL)-BENZAMIDE ET DE 3-[(HYDRAZONO)MÉTHYL]-N-(1,3,4-OXADIAZOL-2-YL)-BENZAMIDE UTILISÉS EN TANT QU'HERBICIDES
  申请人：SYNGENTA CROP PROTECTION AG

  公开号：WO2021013969A1

  公开（公告）日：2021-01-28

  The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4, R5 and R6 are as described herein. The invention further relates to compositions comprising said compounds, to methods of controlling weeds using said compositions, and to the use of compounds of Formula (I) as a herbicide.

  本发明涉及以下式（I）的化合物或其农业上可接受的盐，其中Q、R2、R3、R4、R5和R6如本文所述。该发明还涉及包含所述化合物的组合物，使用这些组合物控制杂草的方法，以及将式（I）的化合物用作除草剂的用途。
• [EN] HERBICIDALLY ACTIVE HETEROARYL-S?BSTIT?TED CYCLIC DIONES OR DERIVATIVES THEREOF<br/>[FR] DIONES CYCLIQUES SUBSTITUÉES PAR HÉTÉROARYLE À ACTIVITÉ HERBICIDE OU DÉRIVÉS DE CELLES-CI
  申请人：SYNGENTA LTD

  公开号：WO2011012862A1

  公开（公告）日：2011-02-03

  The invention relates to a compound of formula (I), which is suitable for use as a herbicide wherein G is hydrogen or an agriculturally acceptable metal, sulfonium, ammonium or latentiating group; Q is a unsubstituted or substituted C3-C8 saturated or mono-unsaturated heterocyclyl containing at least one heteroatom selected from O, N and S, or Q is heteroaryl or substituted heteroaryl; m is 1, 2 or 3; and Het is an optionally substituted monocyclic or bicyclic heteroaromatic ring; and wherein the compound is optionally an agronomically acceptable salt thereof.

  该发明涉及一种化合物，其化学式为(I)，适用作为除草剂，其中G为氢或农业可接受的金属、磺酸盐、铵盐或潜伏基团；Q为未取代或取代的含有至少一个来自O、N和S的杂原子的饱和或单不饱和的C3-C8杂环烷基，或Q为杂芳基或取代的杂芳基；m为1、2或3；Het为可选择地取代的单环或双环杂芳环；且该化合物可选择地为其农学上可接受的盐。
• [EN] NOVEL HERBICIDES<br/>[FR] NOUVEAUX HERBICIDES
  申请人：SYNGENTA LTD

  公开号：WO2009015877A1

  公开（公告）日：2009-02-05

  Bicyclic dione compounds, and derivatives thereof, which are suitable for use as herbicides. formula (I)

  双环二酮化合物及其衍生物，适用于用作除草剂。公式（I）
• [EN] HERBICIDAL PROPYNYL-PHENYL COMPOUNDS<br/>[FR] COMPOSÉS PROPYNYLE-PHÉNYLE HERBICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2015197468A1

  公开（公告）日：2015-12-30

  The present invention relates to a compound of formula (I) wherein: R1 is C1-C3alkoxy, C1-C2alkoxy-C1-C3alkoxy, C1-C2fluoroalkoxy, ethyl, n-propyl, n-butyl, cyclopropyl or ethynyl; R2 is hydrogen, ethyl, n-propyl, cyclopropyl, vinyl, ethynyl, C1-C3alkoxy, C1-C3fluoroalkyl, C1-C2fluoroalkoxy, C1-C2alkoxy-C1-C3alkoxy-, or C1fluoroalkoxy-C1-C3alkoxy-; provided that when R1 is ethyl, n-propyl, n-butyl, cyclopropyl or ethynyl, then R2 is hydrogen, ethyl, n-propyl, cyclopropyl, vinyl or ethynyl; and Y is O, S, S(O), S(O)2, N(C1-C2alkyl), N(C1-C2alkoxy), C(O), CR8R9 or -CR10R11CR12R13-; and and G, R3, R4, R5 and R6 are as defined herein; wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt thereof. These compounds are suitable for use as herbicides. The invention therefore also relates to a method of controlling weeds, especially grassy monocotyledonous weeds, in crops of useful plants, comprising applying a compound of formula (I), or a herbicidal composition comprising such a compound, to the plants or to the locus thereof.

  本发明涉及一种具有以下结构的化合物（I）：其中：R1为C1-C3烷氧基，C1-C2烷氧基-C1-C3烷氧基，C1-C2氟烷氧基，乙基，正丙基，正丁基，环丙基或乙炔基；R2为氢，乙基，正丙基，环丙基，乙烯基，乙炔基，C1-C3烷氧基，C1-C3氟烷基，C1-C2氟烷氧基，C1-C2烷氧基-C1-C3烷氧基，或C1氟烷氧基-C1-C3烷氧基-；但是当R1为乙基，正丙基，正丁基，环丙基或乙炔基时，R2为氢，乙基，正丙基，环丙基，乙烯基或乙炔基；Y为O，S，S(O)，S(O)2，N(C1-C2烷基)，N(C1-C2烷氧基)，C(O)，CR8R9或-CR10R11CR12R13-；以及G，R3，R4，R5和R6如本文所定义；其中化合物（I）可作为农药中可接受的盐存在。这些化合物适用于用作除草剂。因此，本发明还涉及一种控制杂草，特别是草本单子叶杂草，在有用植物作物中的方法，包括将化合物（I）或含有这种化合物的除草剂组合物施用于植物或其生长地点。
• [EN] HERBICIDAL COMPOUNDS<br/>[FR] COMPOSÉS HERBICIDES
  申请人：SYNGENTA CROP PROTECTION AG

  公开号：WO2021209383A1

  公开（公告）日：2021-10-21

  The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to methods of controlling weeds using said compositions, and to the use of Compounds of Formula (I) as a herbicide.

  本发明涉及式（I）的化合物或其农学上可接受的盐，其中Q、R2、R3、R4和R5如本文所述。该发明还涉及包含所述化合物的组合物，使用这些组合物控制杂草的方法，以及将式（I）的化合物用作除草剂的用途。

表征谱图